drugset
drugset / Trial / NCT06713148

Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

NCT06713148 ↗

Phase 0 Not yet recruiting 42 enrolled Fudan University
NaSequentialOpen-labelTreatment

Summary

This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of intratumoral Administration of IDOV-SAFETM in patients with advanced solid tumors.

Timeline

Start
2025-04-10
Primary completion
2025-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IDOV-SAFETM Other / unclassified 1e+08 unknown Other
Subject IDOV-SAFETM Other / unclassified 3e+08 unknown Other
Subject IDOV-SAFETM Other / unclassified 7e+08 unknown Other
Subject IDOV-SAFETM Other / unclassified 1e+09 unknown Other
Subject IDOV-SAFETM Other / unclassified 3e+09 unknown Other

Indications

cancer